Back

Bridging cancer and heart health: insights from a cardio-oncology consultation program at a tertiary university hospital

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology - diagnostic and therapeutic advances Cardio-Oncology HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Catarina Gregorio

Centro Hospitalar Universitário Lisboa Norte, Lisbon (Portugal)

5 More presentations in this session

Presentation thumbnail
GLP1-RA associated with PCSK9i as new therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Use of guideline directed medical therapy and clinical outcomes in cancer patients with de novo heart failure
Doctor Y. Sener (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
The GLP1RA Semaglutide exerts significant cardioprotective properties against anthracycline+/-trastuzumab induced cardiotoxicity: biochemical evidences
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Detecting global cardiac involvement in breast cancer: the GAVS index
Doctor C. Madaudo (Palermo, IT)
Abstract Slides Video
Presentation thumbnail
Echocardiographic indices of right ventricular function to predict cardiovascular outcomes in asian patients with cardiac amyloidosis
Doctor N. Sari (Jakarta, ID)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology - diagnostic and therapeutic advances

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Cardiovascular disease is a significant contributor to the incidence of cancer, second-primary cancer, and cancer-related hospitalization
thumbnail
Congress Presentation
Cardioprotective strategies and outcomes in cancer therapy-related cardiac dysfunction: insights from a single-center study
thumbnail
Congress Presentation
Morbidity and mortality of cardio-oncology patients: is there any link to baseline cardiovascular risk?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources